Blank Bio
Summer 2025RNA-based AI for better drugs and smarter clinical trials.
About Company
Blank Bio builds foundation models that understand RNA, the language of life. Our model powers applications across the entire R&D pipeline, from designing better drugs to running smarter clinical trials. Our first model is state-of-the-art in mRNA property prediction. It simulates costly experiments, helping partners design more effective mRNA medicines faster and cheaper. Our open-source models are being used by Sanofi & GSK. We’re also collaborating with the Arc Institute to bring our RNA embeddings into the next generation of virtual cell models. mRNA design is just the beginning. As the model improves, we’re extending to applications like target ID, novel biomarker discovery, patient stratification, and more. We’ve spent decades applying machine learning to biology across academia (PhDs at the University of Toronto) and industry (Recursion, Deep Genomics, Amazon). Contact us to learn more: founders@blank.bio
Active Founders
Working on foundation models for RNA therapeutics. I was an early employee at Valence Discovery, a biotech startup that spun out from Mila. I led product and strategy. Valence was acquired by Recursion (NASDAQ: RXRX) in May 2023. I stayed on afterwards to help build out the AI research engine of Recursion called Valence Labs. Biochemist by training | Waterloo graduate
Building AI for the most designable molecule in the world: RNA Published at top ML & Bio conferences including best paper at Foundation models for science @ Neurips. Built self-supervised learning applications for RNA, small molecules, and phenomics. Playing long term games in ML for Biology. One of the first employees at Deep Genomics. PhD from University of Toronto.
Building foundational models for RNA therapeutics at Blank Bio. Just defended my PhD in CS at the University of Toronto. Published at ICML, NeurIPS, Nature Comms; used 4 GPUs to pre-train an mRNA foundation model that beat competitors using months of compute on thousands of H100s. Now scaling our models to unlock new possibilities in the RNA therapeutic space. Previously at Amazon building software, interned at Pinterest and Amazon as a research scientist in between.